Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?
作者： Kristina Lindsley , Tianjing Li , Elizabeth Ssemanda , Gianni Virgili , Kay Dickersin
DOI: 10.1016/J.OPHTHA.2015.12.004
关键词:
摘要: Purpose Are existing systematic reviews of interventions for age-related macular degeneration incorporated into clinical practice guidelines? Design High-quality should be used to underpin evidence-based guidelines and care. We examined the reliability (AMD) described main findings reliable in relation guidelines. Methods Eligible publications were effectiveness treatment AMD. searched a database eyes vision without language or date restrictions; was up as May 6, 2014. Two authors independently screened records eligibility abstracted assessed characteristics methods each review. classified when they reported criteria, comprehensive searches, methodologic quality included studies, appropriate statistical meta-analysis, conclusions based on results. mapped recommendations from American Academy Ophthalmology (AAO) Preferred Practice Patterns (PPPs) AMD citations support recommendation. Results Of 1570 our database, 47 met inclusion criteria; most targeted neovascular investigated anti–vascular endothelial growth factor (VEGF) interventions, dietary supplements, photodynamic therapy. 33 (70%) reliable. The reporting varied, with criteria more often by Cochrane whose disclosed conflicts interest. Anti-VEGF agents therapy only identified effective reviews. 35 extracted PPPs, 15 could have been supported reviews; however, 1 recommendation cited intervention No review 20 recommendations, highlighting areas evidence gaps. Conclusions For AMD, exist many AAO PPPs these recommendations. also where no high-level exists. Mapping is one way highlight generation synthesis either available needed.
elsevier.com
sci-hub.se 参考文章(101)
Focke Ziemssen, Salvatore Grisanti, Karl Ulrich Bartz-Schmidt, Martin S. Spitzer, Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs & Aging. ,vol. 26, pp. 295- 320 ,(2009) , 10.2165/00002512-200926040-00002
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Archives of Ophthalmology. ,vol. 121, pp. 1621- 1624 ,(2003) , 10.1001/ARCHOPHT.121.11.1621
Michelle Mancher, Dianne Miller Wolman, Sheldon Greenfield, Robin Graham, Earl Steinberg, Clinical Practice Guidelines We Can Trust ,(2013)
Tianjing Li, Kay Dickersin, Citation of previous meta-analyses on the same topic: a clue to perpetuation of incorrect methods? Ophthalmology. ,vol. 120, pp. 1113- 1119 ,(2013) , 10.1016/J.OPHTHA.2012.11.038
J Arnold, D Kilmartin, J Olson, S Neville, K Robinson, A Laird, C Richmond, A Farrow, S McKay, DA Saperstein, TM Aaberg, JB Johnson, R Waldron, D Loupe, J Gillman, B Myles, AP Schachat, NM Bressler, SB Bressler, P Nesbitt, T Porter, P Hawse, M Hartnett, A Eager, J Belt, D Cain, D Emmert, T George, M Herring, J McDonald, J Mones, B Corcostegui, M Gilbert, N Duran, M Sisquella, A Nolla, A Margalef, JW Miller, ES Gragoudas, AM Lane, N Emmanuel, A Holbrook, C Evans, US Lord, DK Walsh, CD Callahan, JL DuBois, H Lewis, PK Kaiser, LJ Holody, E Lesak, S Lichterman, H Siegel, A Fattori, G Ambrose, T Fecko, D Ross, S Burke, L Singerman, H Zegarra, M Novak, M Bartel, K Tilocco-DuBois, M Iic, S Schura, SJ Mayes, V Tanner, P Rowe, S Smith-Brewer, D Kukula, G Greanoff, G Daley, J DuBois, D Lehnhardt, GE Fish, BF Jost, R Anand, D Callanan, S Arceneaux, J Arnwine, P Ellenich, J King, H Aguado, R Rollins, B Jurklies, D Pauleikhoff, A Hintzmann, M Fischer, C Sowa, E Behne, CJ Pournaras, G Donati, AD Kapetanios, K Cavaliere, S Guney-Wagner, N Gerber, M Sickenberg, V Sickenberg, A Gans, B Hosner, A Sbressa, C Kozma, M Curchod, SA Cancelli, S Harding, YC Yang, M Briggs, S Briggs, V Tompkin, R Jackson, S Pearson, S Natha, J Sharp, JI Lim, C Flaxel, M Padilla, L Levin, F Walonker, L Cisneros, T Nichols, U Schmidt-Erfurth, I Barbazetto, H Laqua, R Kupfer, R Bulow, B Glisovic, T Bredfeldt, H Elsner, V Wintzer, D Bahlmann, S Michels, MS Blumenkranz, HL Little, R Jack, LM Espiritu, L Unyi, J Regan, L Lamborn, C Silvestri, RH Rosa, PJ Rosenfeld, ML Lewis, B Rodriguez, A Torres, N Munoz, T Contreras, M Galvez, D Hess, T Cubillas, I Rams, None, Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin - 1-year results of a randomized clinical trial - VIP report no. 1 Ophthalmology. ,vol. 108, pp. 841- 852 ,(2001) , 10.1016/S0161-6420(01)00544-9
Daniel F Martin, Maureen G Maguire, GSet al Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe, None, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. ,vol. 364, pp. 1897- 1908 ,(2011) , 10.1056/NEJMOA1102673
Usha Reddy, Magdalena Krzystolik, Antiangiogenic therapy with interferon alfa for neovascular age‐related macular degeneration Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD005138.PUB2
Peter C. Smith, Michael Forman, Paul A. Lovoi, Treatment of age-related macular degeneration ,(2004)
Jeffrey S. Heier, Andrew N. Antoszyk, Peter Reed Pavan, Steven R. Leff, Philip J. Rosenfeld, Thomas A. Ciulla, Richard F. Dreyer, Ronald C. Gentile, Judy P. Sy, Gary Hantsbarger, Naveed Shams, Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. ,vol. 113, pp. 633- 642 ,(2006) , 10.1016/J.OPHTHA.2005.10.052
R. Hahn, S. Sacu, S. Michels, A. Varga, G. Weigert, W. Geitzenauer, P. Vécsei-Marlovits, U. Schmidt-Erfurth, Intravitreales Bevacizumab vs. Verteporfin und intravitreales Triamcinolon Acetonid bei Patienten mit neovaskulärer AMD Ophthalmologe. ,vol. 104, pp. 588- 593 ,(2007) , 10.1007/S00347-007-1547-4